Search
How developmental biologist Eric Lai’s approach to science co-evolved with his music, art, and life outside the lab.
Discover some of the latest innovations in chemotherapy for breast cancer.
Learn how tiny sensors made of nanotubes could serve as implantable devices that offer a noninvasive way to monitor cancer and its treatments.
Dr. Bob Li will present registrational phase II data from the first-ever trial of a drug that blocks cancer gene KRAS.
Learning more about epithelioid hemangioendothelioma (EHE) is an ongoing mission of MSK’s sarcoma research.
Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (COTELLIC®) for the treatment of adult patients with the family of blood diseases know as histiocytic neoplasms (HN). These diseases include: Erdheim-Chester Disease, Rosai-Dorfman, and Langerhans Histiocytosis. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma.
Learn how high-intensity focused ultrasound (HIFU) can help some men with prostate cancer avoid surgery or radiation.
Research by a team at Memorial Sloan Kettering Cancer Center has found important new insights into colorectal cancer in Nigeria that have significant implications for treating the disease in West Africa. This research also expands awareness of how different population groups may require different approaches in the diagnosis and treatment of cancer.
The Patient and Family Advisory Council for Quality (PFACQ) marks five years of ensuring the patient and family perspective is included in everything MSK does.
Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries molecular changes called NPM1 mutations and KMT2A translocations.